Pharmspective releases ‘Molecular Diagnostics Insights in Oncology’

Pharmspective, LLC today announced the release of its second syndicated report – Molecular Diagnostics Insights in Oncology. This new extensive survey of over 400 oncologists characterizes the emerging molecular diagnostics landscape and the role and influence of specific assays in clinical management and therapy selection.

Molecular Diagnostics Insights in Oncology includes:

• Detailed information regarding the role and influence of cancer diagnostics in disease staging, treatment monitoring, and therapy selection
• The effect of diagnostic test results on insurer reimbursement and treatment authorization
• Insight into the role and influence of specific cancer diagnostics manufacturers in shaping perception and decision-making involving molecular diagnostics
• Identification of the targeted therapies that are most impacted by the emerging assays

"The research and planning that we undertook to build a research tool that could comprehensively and accurately capture current practices with molecular diagnostics was an exhaustive one," according to Katie Derdeyn, MD, Managing Partner. "The insights that this survey has produced will prove invaluable to pharma and biotech executives who are keenly interested in understanding how these tests are influencing treatment decisions."

Pharmspective at American Society of Clinical Oncology Annual MeetingDr. Derdeyn and the Pharmspective team will discuss Molecular Diagnostics Insights in Oncology at the American Society of Clinical Oncology Annual Meeting Exhibit Hall from June 2 through June 4. The Pharmspective™ information booth and kiosk will be at Booth 11136 in the McCormick Convention Center, Chicago, Illinois.

"With over 30,000 attendees, the ASCO Annual Meeting is one of the largest educational and scientific events in the oncology community and introducing Molecular Diagnostics Insights in Oncology at this venue will provide the right platform to begin a dialogue on the survey's key findings," says Dr. Derdeyn.   

Pharmspective is a specialty therapeutics market research firm providing commercial insights and knowledge management applications for the biopharmaceutical industry.

Pharmspective Proprietary Syndicated Research Studies Cover:

• Identification of key decision drivers across the specialty therapeutics prescribing continuum
• Profiling of the drug acquisition and reimbursement process and related barriers to therapy adoption
• Insight into new factors that are influencing prescribing decisions

In 2012, Pharmspective will release syndicated research studies in the following areas:

• Cancer Molecular Diagnostics and other Oncology conditions
• Rheumatoid Arthritis
• Crohn's/Ulcerative Colitis
• Lupus
• Multiple Sclerosis
• Psoriasis